Table 2.
Association of PD-L1 staining with clinicopathologic factors in all patients with neoadjuvant chemotherapy
| TC | TCIC | IC | sTIL level | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Factors | Negative | Positive | Fisher | Negative | Positive | Fisher | Negative | Positive | Fisher | Low | High | Fisher |
| N (%) | N (%) | P value | N (%) | N (%) | P value | N (%) | N (%) | P value | N (%) | N (%) | P value | |
| Age | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| < 50 years | 50 (94) | 3 (6) | 0.535 | 45 (88) | 6 (12) | 0.1651 | 47 (92) | 4 (8) | 0.1257 | 41 (73) | 15 (27) | 0.557 |
| ≥ 50 years | 79 (90) | 9 (10) | 62 (78) | 18 (23) | 65 (81) | 15 (19) | 69 (78) | 20 (22) | ||||
| Race/ethnicity | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| Black | 19 (79) | 5 (21) | 0.0228 | 18 (75) | 6 (25) | 0.5126 | 20 (83) | 4 (17) | 0.9225 | 16 (70) | 7 (30) | 0.6991 |
| White+Latino | 97 (95) | 5 (5) | 78 (84) | 15 (16) | 80 (86) | 13 (14) | 82 (77) | 24 (23) | ||||
| Others | 13 (87) | 2 (13) | 11 (79) | 3 (21) | 12 (86) | 2 (14) | 12 (75) | 4 (25) | ||||
| Histologic type | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| IDC | 106 (91) | 10 (9) | 0.0737 | 85 (79) | 22 (21) | 0.0624 | 89 (83) | 18 (17) | 0.2508 | 87 (73) | 33 (28) | 0.1731 |
| ILC | 17 (100) | 0 (0) | 16 (100) | 0 (0) | 16 (100) | 0 (0) | 16 (94) | 1 (6) | ||||
| Metaplastic | 3 (60) | 2 (40) | 3 (60) | 2 (40) | 4 (80) | 1 (20) | 4 (80) | 1 (20) | ||||
| Mixed IDC/ILC | 3 (100) | 0 (0) | 3 (100) | 0 (0) | 3 (100) | 0 (0) | 3 (100) | 0 (0) | ||||
| Histologic gradea | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| 1 + 2 | 68 (100) | 0 (0) | 0.0003 | 62 (95) | 3 (5) | 0.0001 | 62 (95) | 3 (5) | 0.0022 | 65 (88) | 9 (12) | 0.0008 |
| 3 | 61 (84) | 12 (16) | 45 (68) | 21 (32) | 50 (76) | 16 (24) | 45 (63) | 26 (37) | ||||
| sTIL level | [N = 139] | [N = 131] | [N = 131] | NA | ||||||||
| < 10% | 102 (97) | 3 (3) | 0.0002 | 89 (91) | 9 (9) | < 0.0001 | 90 (92) | 8 (8) | 0.0006 | |||
| ≥ 10% | 25 (74) | 9 (26) | 16 (52) | 15 (48) | 20 (65) | 11 (35) | ||||||
| ER | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| Negative | 30 (77) | 9 (23) | 0.0005 | 20 (57) | 15 (43) | < 0.0001 | 24 (69) | 11 (31) | 0.0019 | 22 (56) | 17 (44) | 0.0018 |
| Positive | 99 (97) | 3 (3) | 87 (91) | 9 (9) | 88 (92) | 8 (8) | 88 (83) | 18 (17) | ||||
| PR | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| Negative | 48 (83) | 10 (17) | 0.0037 | 34 (67) | 17 (33) | 0.0009 | 39 (76) | 12 (24) | 0.0236 | 36 (62) | 22 (38) | 0.0026 |
| Positive | 81 (98) | 2 (2) | 73 (91) | 7 (9) | 73 (91) | 7 (9) | 74 (85) | 13 (15) | ||||
| HER2 | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| Negative | 118 (91) | 12 (9) | 0.5987 | 98(81) | 23 (19) | 0.6881 | 103 (85) | 18 (15) | 1 | 99 (75) | 33 (25) | 0.7344 |
| Positive | 11 (100) | 0 (0) | 9(90) | 1 (10) | 9 (90) | 1 (10) | 11 (85) | 2 (15) | ||||
| TNBC | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| No | 101 (97) | 3 (3) | 0.0003 | 88 (91) | 9 (9) | < 0.0001 | 89 (92) | 8 (8) | 0.0014 | 90 (83) | 18 (17) | 0.0007 |
| Yes | 28 (76) | 9 (24) | 19 (56) | 15 (44) | 23 (68) | 11 (32) | 20 (54) | 17 (46) | ||||
| Receptor group | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| ER/PR pos | 90 (97) | 3 (3) | 0.0012 | 79 (91) | 8 (9) | 0.0001 | 80 (92) | 7 (8) | 0.0038 | 79 (83) | 16 (17) | 0.0023 |
| HER2 | 11 (100) | 0 (0) | 9 (90) | 1 (10) | 9 (90) | 1 (10) | 11 (85) | 2 (15) | ||||
| TNBC | 28 (76) | 9 (24) | 19 (56) | 15 (44) | 23 (68) | 11 (32) | 20 (54) | 17 (46) | ||||
| Tumor size | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| ≤ 2 cm | 26 (84) | 5 (16) | 0.2433 | 19 (73) | 7 (27) | 0.4286 | 20 (77) | 6 (23) | 0.3765 | 21 (62) | 13 (38) | 0.049 |
| > 2 to 5 cm | 54 (93) | 4 (7) | 49 (84) | 9 (16) | 51 (88) | 7 (12) | 43 (75) | 14 (25) | ||||
| > 5 cm | 49 (94) | 3 (6) | 39 (83) | 8 (17) | 41 (87) | 6 (13) | 46 (85) | 8 (15) | ||||
| ypN | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| (y)pN0 | 39 (85) | 7 (15) | 0.0921 | 33 (77) | 10 (23) | 0.6247 | 36 (84) | 7 (16) | 0.9424 | 35 (74) | 12 (26) | 0.3048 |
| (y)pN1 | 45 (96) | 2 (4) | 36 (84) | 7 (16) | 36 (84) | 7 (16) | 37 (74) | 13 (26) | ||||
| (y)pN2 | 22 (88) | 3 (12) | 19 (79) | 5 (21) | 21 (88) | 3 (13) | 18 (69) | 8 (31) | ||||
| (y)pN3 | 23 (100) | 0 (0) | 19 (90) | 2 (10) | 19 (90) | 2 (10) | 20 (91) | 2 (9) | ||||
| pM | [N = 141] | [N = 131] | [N = 131] | [N = 145] | ||||||||
| 0 | 119 (91) | 12 (9) | 1 | 101 (82) | 22 (18) | 0.6382 | 106 (86) | 17 (14) | 0.3272 | 100 (74) | 35 (26) | 0.1184 |
| 1 | 10 (100) | 0 (0) | 6 (75) | 2 (25) | 6 (75) | 2 (25) | 10 (100) | 0 (0) | ||||
| RCB category | [N = 140] | [N = 130] | [N = 130] | [N = 144] | ||||||||
| I | 4 (80) | 1 (20) | 0.5155 | 3 (75) | 1 (25) | 0.4125 | 3 (75) | 1 (25) | 0.2473 | 5 (83) | 1 (17) | 0.9425 |
| II | 63 (91) | 6 (9) | 54 (86) | 9 (14) | 57 (90) | 6 (10) | 56 (77) | 17 (23) | ||||
| III | 61 (92) | 5 (8) | 49 (78) | 14 (22) | 51 (81) | 12 (19) | 48 (74) | 17 (26) | ||||
aHistologic grade for post-treatment tumors was based on pre-treatment grade
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, pos positive, RCB residual cancer burden